1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65770769DD7FE50B300258A380025B849
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-rare-blood-disorders-msl-team-excellence-benchmarking-key-performance-indicators?opendocument
18
19opendocument
2034.228.52.21
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Field Medical Excellence

Rare Blood Disorders MSL Team Excellence: Benchmarking Key Performance Indicators

ID: 5781


Features:

12 Info Graphics

11 Data Graphics

90+ Metrics

15 Narratives


Pages/Slides: 28


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Rare Blood Disorders MSL Team Excellence: Benchmarking Key Performance Indicators”

STUDY OVERVIEW

In a landscape marked by continual changes, Rare Blood Disorders field medical teams need to keep up with a combination of traditional as well as virtual interactions to effectively engage with KOLs. To successfully adapt to this new environment, it's imperative to establish and evaluate key performance indicators (KPIs) that gauge field performance and impact.

Best Practices, LLC's benchmarking research uncovers current and emerging trends around managing field-based, hybrid and virtual MSLs in Rare Blood Disorders therapeutic area. This study offers a comprehensive guide to establishing meaningful KPIs, tracking field performance, and evaluating the far-reaching impact of field medical teams.


KEY TOPICS

  • Field Challenges
  • KOL Access - Post Pandemic
  • Customer Engagement Preference
  • Proactive Outreach
  • F2F Meetings: Value and Ideal Mix

KEY METRICS

  • How would you rate the post-pandemic ability of Rare Blood Disorders MSLs to interact with KOLs and HCPs?
  • What do KOLs and HCPs served by Rare Blood Disorders MSL teams prefer in terms of engagement and support?
  • Approximately how many KOLs are currently supported by an individual MSL of each type at Rare Blood Disorders organizations?
  • Approximately how many F2F and virtual meetings are asked of each MSL within the Rare Blood Disorders organization?
  • Percentage of proactive interactions in Rare Blood Disorders segment
  • MSL proactivity index in Rare Blood Disorders segment
  • Are F2F interactions assigned a higher value on the Rare Blood Disorders MSL scorecard?
  • How many F2F meetings are targeted monthly?

SAMPLE KEY FINDINGS

  • Proactive outreach and product-specific discussion: On average, field-based MSLs initiate 57% of KOL interactions, proactively discussing products in 63% of these interactions. This equates to a baseline “Proactive Product” outreach index of 36% of all interactions, or 5.4 F2F and 3.9 virtual Proactive Product engagements per MSL per month.

METHODOLOGY

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 17 top Rare Blood Disorders manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Agios; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Astellas; Bayer; BioMarin; Chiesi; CSL Behring; Fresenius Medical Care; Kyowa Kirin; Legend Biotech; Novartis; Novo Nordisk; Servier; Sobi; Takeda Pharmaceuticals; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.